Clinical Trial Update: Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial investigates using ideal body weight to guide sugammadex dosing for reversing profound rocuronium-induced neuromuscular blockade in morbid obesi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity

Drugs mentioned

• ROCURONIUM BROMIDE (ROCURONIUM BROMIDE)
• Sugammadex (sugammadex)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Morbid Obesity | Phase 2 | Status: COMPLETED